CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 257 enrolled
Drug / intervention
0.3% YP-P10 Ophthalmic Solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05467293
NCT05467293Phase 2Completed
CompareCT.gov

A Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

Yuyu Pharma, Inc.·interventional·Posted Jul 20, 2022·Updated Jul 30, 2024

In Brief

A Phase 2 clinical trial evaluating 0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution, and 1 other intervention for Dry Eye. Completed, enrolled 257 participants across 7 sites.

Detailed Summary

The objective of this study is to compare the safety and efficacy of YP-P10 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJul 20, 2022
Enrollment StartJun 27, 2022
Primary CompletionMar 6, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.9 years ago

Interventions

0.3% YP-P10 Ophthalmic Solutiondrug

Drug: YP-P10 Ophthalmic Solution

1% YP-P10 Ophthalmic Solutiondrug

Drug: YP-P10 Ophthalmic Solution

YP-P10 Placebo Ophthalmic Solution (vehicle)drug

Placebo YP-P10 Placebo Ophthalmic Solution (vehicle)